keyword
MENU ▼
Read by QxMD icon Read
search

"Hepatitis c" cost

keyword
https://www.readbyqxmd.com/read/28078810/anti-hcv-activity-from-semi-purified-methanolic-root-extracts-of-valeriana-wallichii
#1
Krishna Kumar Ganta, Anirban Mandal, Sukalyani Debnath, Banasri Hazra, Binay Chaubey
Hepatitis C virus (HCV) is a serious global health problem affecting approximately 130-150 million individuals. Presently available direct-acting anti-HCV drugs have higher barriers to resistance and also improved success rate; however, cost concerns limit their utilization, especially in developing countries like India. Therefore, development of additional agents to combat HCV infection is needed. In the present study, we have evaluated anti-HCV potential of water, chloroform, and methanol extracts from roots of Valeriana wallichii, a traditional Indian medicinal plant...
January 12, 2017: Phytotherapy Research: PTR
https://www.readbyqxmd.com/read/28060834/estimating-the-cost-effectiveness-of-one-time-screening-and-treatment-for-hepatitis-c-in-korea
#2
Do Young Kim, Kwang-Hyub Han, Byungyool Jun, Tae Hyun Kim, Sohee Park, Thomas Ward, Samantha Webster, Phil McEwan
BACKGROUND AND AIMS: This study aims to investigate the cost-effectiveness of a one-time hepatitis C virus (HCV) screening and treatment program in South Korea where hepatitis B virus (HBV) prevails, in people aged 40-70, compared to current practice (no screening). METHODS: A published Markov model was used in conjunction with a screening and treatment decision tree to model patient cohorts, aged 40-49, 50-59 and 60-69 years, distributed across chronic hepatitis C (CHC) and compensated cirrhosis (CC) health states (82...
2017: PloS One
https://www.readbyqxmd.com/read/28053553/hepatitis-c-in-egypt-past-present-and-future
#3
REVIEW
Ahmed Elgharably, Asmaa I Gomaa, Mary Me Crossey, Peter J Norsworthy, Imam Waked, Simon D Taylor-Robinson
Hepatitis C viral infection is endemic in Egypt with the highest prevalence rate in the world. It is widely accepted that the implementation of mass population antischistosomal treatment involving administration of tartar emetic injections (from 1950s to 1980s) led to widespread infection. What is less well known, however, is that these schemes were implemented by the Egyptian Ministry of Health on the advice of the World Health Organization. There has been a spectrum of treatments to target the public health disaster represented by the hepatitis C problem in Egypt: from the use of PEGylated interferon to the recent use of direct acting antiviral drugs...
2017: International Journal of General Medicine
https://www.readbyqxmd.com/read/28052634/treatment-of-chronic-hepatitis-b-infection-2017
#4
REVIEW
Guo-Feng Chen, Cheng Wang, George Lau
Since the registration of the first effective nucleoside analogue against the hepatitis B virus almost two decades ago, major progress has been made in the management of chronic hepatitis B infection. However, hepatitis B-related morbidity and mortality remain a major global health threat. This is partly due to the escalating costs and the decrease in compliance related to the need for prolonged therapy for most patients who cannot be "cured". New biomarkers such as quantitative hepatitis B surface antigen might help to determine if hepatitis B e antigen negative patients can be taken off nucleos(t)ide analogues...
January 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28051283/incremental-cost-effectiveness-pharmacoeconomic-assessment-of-hepatitis-c-virus-therapy-an-approach-for-less-wealthy-members-of-the-common-market
#5
Diana Mance, Davor Mance, Dinko Vitezić
AIM: To develop a new method of health-economic analysis based on a marginal approach. METHODS: We tested the research hypothesis that a detailed comparative a priori incremental cost-effectiveness analysis provides the necessary input for budget impact analysis about the proper order of introduction of new therapies, and thus maximizes the cost-effectiveness bounded by the total budget constraint. For the analysis we chose a combination therapy for the treatment of hepatitis C virus (HCV) genotype 1 (GT1) infection, which was approved by the European Medicine Agency in 2015...
December 31, 2016: Croatian Medical Journal
https://www.readbyqxmd.com/read/28046099/cost-effectiveness-of-treating-hepatitis-c-with-sofosbuvir-ledipasvir-in-germany
#6
Jona T Stahmeyer, Siegbert Rossol, Sebastian Liersch, Ines Guerra, Christian Krauth
BACKGROUND: Infections with the hepatitis C virus (HCV) are a global public health problem. Long-term consequences are the development of liver cirrhosis and hepatocellular carcinoma. Newly introduced direct acting antivirals, especially interferon-free regimens, have improved rates of sustained viral response above 90% in most patient groups and allow treating patients who were ineligible for treatment in the past. These new regimens have replaced former treatment and are recommended by current guidelines...
2017: PloS One
https://www.readbyqxmd.com/read/28041821/nat-positivity-in-seronegative-voluntary-blood-donors-from-western-india
#7
Kanchan K Mishra, Apeksha Trivedi, Sheetal Sosa, Krima Patel, Kanjaksha Ghosh
BACKGROUND AND OBJECTIVES: Prevalence and composition of Hepatitis B, Hepatitis C and HIV-1, NAT positive but seronegative voluntary blood donors from western part of India is yet to be documented. MATERIAL AND METHODS: Over last 2 1/2 years all the seronegative voluntary blood donors were tested using 10 minipools on a semiautomated NAT testing platform. The positively tested donors were followed up for at least five months for development of seropositivity. RESULTS: 79532 seronegative donations were tested by 10 minipool (MP) NAT leading to 51 positive sample (44 Hep B, 5 HIV 1 and Hep C positive)...
December 13, 2016: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/28034492/addition-of-ribavirin-to-daclatasvir-plus-asunaprevir-for-chronic-hepatitis-c-1b-patients-with-baseline-ns5a-resistance-associated-variants-improved-response
#8
Chun-Ming Hong, Chun-Jen Liu, Shiou-Hwei Yeh, Pei-Jer Chen
BACKGROUND/PURPOSE: Daclatasvir is a nonstructural protein 5A inhibitor with potent activity against hepatitis C virus genotypes 1-6 in vitro, and asunaprevir is a nonstructural protein 3 protease inhibitor with activity against genotypes 1, 4, 5, and 6. Despite a 90% sustained virologic response (SVR) rate, the SVR rate in patients with baseline NS5A-L31/Y93H polymorphisms decreased to around 40%. Therefore, an alternative regimen under the consideration of cost-effectiveness would be important...
December 26, 2016: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/28018873/restrictions-for-reimbursement-of-direct-acting-antiviral-treatment-for-hepatitis-c-virus-infection-in-canada-a-descriptive-study
#9
Alison D Marshall, Sahar Saeed, Lisa Barrett, Curtis L Cooper, Carla Treloar, Julie Bruneau, Jordan J Feld, Lesley Gallagher, Marina B Klein, Mel Krajden, Naglaa H Shoukry, Lynn E Taylor, Jason Grebely
BACKGROUND: In Canada, interferon-free, direct-acting antiviral hepatitis C virus (HCV) regimens are costly. This presents challenges for universal drug coverage of the estimated 220 000 people with chronic HCV infection nationwide. The study objective was to appraise criteria for reimbursement of 4 HCV direct-acting antivirals in Canada. METHODS: We reviewed the reimbursement criteria for simeprevir, sofosbuvir, ledipasvir-sofosbuvir and paritaprevir-ritonavir-ombitasvir plus dasabuvir in the 10 provinces and 3 territories...
October 2016: CMAJ Open
https://www.readbyqxmd.com/read/28008546/cost-effectiveness-analysis-of-the-use-of-daclatasvir%C3%A2-%C3%A2-sofosbuvir%C3%A2-%C3%A2-ribavirin-16%C3%A2-weeks-and-12%C3%A2-weeks-vs-sofosbuvir%C3%A2-%C3%A2-ribavirin-16%C3%A2-weeks-and-24%C3%A2-weeks-for-the-treatment-of-cirrhotic-patients-affected-with-hepatitis-c-virus-genotype-3-in-italy
#10
Umberto Restelli, Alfredo Alberti, Adriano Lazzarin, Marzia Bonfanti, Carmela Nappi, Davide Croce
The WHO estimates that more than 185 million people are infected with hepatitis C virus (HCV) worldwide. The aim of the study is to assess the incremental cost-effectiveness ratio (ICER) of the use of daclatasvir (DCV) + sofosbuvir (SOF) + ribavirin (RBV) for 12 and 16 weeks vs SOF + RBV for 16 and 24 weeks for the treatment of genotype 3 HCV infected cirrhotic patients from the Italian National Health Service (NHS) perspective. A published cohort-based Markov model was used to perform the analysis estimating the lifetime direct medical costs associated with the management of the pathology and the quality adjusted life years gained by patients...
December 22, 2016: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28005477/correlates-of-hepatitis-c-virus-infection-in-the-targeted-testing-program-of-the-new-york-city-jail-system
#11
Matthew J Akiyama, Fatos Kaba, Zachary Rosner, Howard Alper, Aimee Kopolow, Alain H Litwin, Homer Venters, Ross MacDonald
OBJECTIVE: The objective of this study was to understand predictors of hepatitis C virus (HCV) antibody positivity in a large urban jail system in New York City. METHODS: We examined demographic characteristics, risk behaviors, and HCV antibody prevalence among 10 790 jail inmates aged 16 to 86 who were screened from June 13, 2013, to June 13, 2014, based on birth cohort or conventional high-risk criteria. We used logistic regression analysis to determine predictors of HCV antibody positivity...
January 2017: Public Health Reports
https://www.readbyqxmd.com/read/28005275/urgency-to-treat-patients-with-chronic-hepatitis-c-in-asia
#12
REVIEW
Jia-Horng Kao, Sang Hoon Ahn, Rong-Nan Chien, Mong Cho, Wan-Long Chuang, Sook-Hyang Jeong, Chen-Hua Liu, Seung-Woon Paik
Chronic hepatitis C (CHC) infection poses a global healthcare burden, being associated with serious complications if untreated. The prevalence of hepatitis C virus (HCV) infection is highest in areas of Central, South and East Asia; over 50% of HCV patients worldwide live in the region, where HCV genotypes 1b, 2, 3, and 6 are the most prevalent. Treatment outcomes for CHC vary by ethnicity, and Asian patients achieve higher sustained virologic response rates following interferon (IFN)-based therapy than non-Asians...
December 22, 2016: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27996693/assessment-of-semi-automated-nucleic-acid-testing-programme-in-a-regional-blood-transfusion-centre
#13
Kanjaksha Ghosh, Kanchan Kumar Mishra, Apeksha Trivedi, Sheetal Sosa, Krima Patel
BACKGROUND: Detection of human immunodeficiency virus type-1 (HIV-1), hepatitis-C (HCV) and hepatitis-B virus (HBV) in the blood donors is crucial. An efficient form of detection is nucleic acid testing (NAT) in blood screening. We assessed the suitability of commercial NAT testing in a developing country, focusing on the Altona RealStar assay and the method of Sacace Biotechnologies. METHODS: We have standardised and validated commercially available NAT kits with a semi-automated system for detection of HBV, HCV and HIV-1 in blood donations...
December 20, 2016: British Journal of Biomedical Science
https://www.readbyqxmd.com/read/27992983/risk-factors-for-hepatitis-c-virus-infection-in-the-colombian-caribbean-coast-a-case-control-study
#14
Ismael de Jesús Yepes, Beatriz Lince, Clara Caez, Giovanni De Vuono
INTRODUCTION: An estimated 6.8-8.9 million people are infected with hepatitis C virus in Latin America, of which less than 1% receives antiviral treatment. Studies so far in Colombia have attempted to determine the prevalence of the disease in some risk groups, thus preventing the identification of other factors potentially involved in the spread of the infection. OBJECTIVES: To identify traditional and non-traditional risk factors for chronic hepatitis C in the Colombian Caribbean coast...
December 1, 2016: Biomédica: Revista del Instituto Nacional de Salud
https://www.readbyqxmd.com/read/27972954/differences-in-cost-effectiveness-estimates-for-chronic-hepatitis-c-treatment-among-cohort-markov-model-markov-microsimulation-and-discrete-event-simulation
#15
H J Zhou, Y J Zhao, A C Wojciech, L Lin, J J Caro, J Moller, Y Y Dan, B P Lim
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27972872/a-cost-utility-analysis-of-different-antiviral-medicine-regimens-in-patients-with-chronic-hepatitis-c-virus-genotype-1-in-iran
#16
S M Alavian, S Nikfar, A Kebriaeezadeh, M Rezaei Hemami, E Sanati, K Keshavarz
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971325/cost-effectiveness-analysis-of-sofosbuvir-and-ledipasvir-sofosbuvir-in-hepatitis-c-virus-hcv-patients
#17
M Ruggeri, F Romano, A Cicchetti
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971319/hepatitis-c-treatment-with-first-generation-protease-inhibitors-in-a-real-world-cohort-risk-benefit-profile-and-costs-of-the-therapy
#18
I Cacciola, C Giardina, V Sirna, R Macrì, A D'Ausilio, A Aiello, E Latorre, M Toumi, R Filomia, G Raimondo, V Arcoraci, A P Caputi
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27970798/cost-effectiveness-of-ombitasvir-paritaprevir-ritonavir-with-or-without-dasabuvir-for-the-treatment-of-chronic-hepatitis-c-patients-infected-with-genotype-1-or-4-in-france
#19
G Sroczynski, A Conrads-Frank, N Mühlberger, F Kühne, G Jeanblanc, J C Samp, I Durand-Zaleski, U Siebert
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27970795/cost-effectiveness-analysis-of-daclatasvir-with-asunaprevir-vs-paritaprevir-ritonavir-ombitasvir-with-dasabuvir-in-treatment-of-chronic-hepatitis-c-in-the-russian-federation
#20
R Yagudina, A Kulikov, V V Babiy
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
90225
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"